Dean Y. Li, MD, PhD
Dean has founded two successful biotech companies (Hydra Biosciences and Navigen), and has been on the cutting-edge of translational medical research at the University of Utah for more than two decades. In fact, Recursion's target-agnostic approach to drug discovery was developed by Dr. Chris Gibson in Dean's University of Utah laboratory. Dean trained at Washington University in Saint Louis before coming to Utah to work as a post-doc in the laboratory of Mark Keating. Dean currently serves as the H.A. & Edna Benning Professor of Medicine and Cardiology at the University of Utah, as the Vice-Dean of research at the University of Utah Health Science Center, and as the Chief Scientific Officer of University of Utah Health Care. Dean also served as interim CEO of Associated Regional University Pathologists (ARUP), the nation's third largest clinical reference laboratory, from 2015 to 2016. Dean will serve as Vice President of Cardiovascular & Metabolic Disease at Merck & Co. beginning in March of 2017.